FIELD: medicine. SUBSTANCE: method involves applying immunoenzyme blood analysis to determine the quantity of antibodies to glycolipid and Escherichia coli. Their ratio is equal to 1.0 ± 0.2, endotoxinemia syndrome is considered to be in remission stage. The value being equal to 2.5 ± 0.4, exacerbation stage is considered to be the case. EFFECT: determined pathogenetic significance of endotoxinemia in bronchial asthma.
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR EVALUATING SEVERITY DEGREE OF THE FLOW OF COMBINED FORMS OF ATOPIC DERMATITIS IN CHILDREN | 2005 |
|
RU2282857C1 |
| METHOD FOR PREDICTING ALLERGIC RHINITIS | 2005 |
|
RU2298187C1 |
| METHOD FOR DIAGNOSTICS OF LATENT DISEASES BASING ON SYSTEMIC ENDOTOXAMIA INDICES | 2015 |
|
RU2609763C1 |
| ANTIALLERGIC AGENT "KATYK" | 1997 |
|
RU2139064C1 |
| EFFICIENCY ESTIMATE OF BASELINE ANTIINFLAMMATORY THERAPY OF BRONCHIAL ASTHMA IN CHILDREN | 2008 |
|
RU2357259C1 |
| METHOD FOR TREATING PSYCHOEMOTIONAL DISORDERS IN CHILDREN AT BRONCHIAL ASTHMA | 1999 |
|
RU2191028C2 |
| METHOD FOR SETTING DIFFERENTIAL DIAGNOSIS OF INFECTION-DEPENDENT AND ATOPIC BRONCHIAL ASTHMA | 2000 |
|
RU2165083C1 |
| METHOD FOR TREATING ATOPIC DERMATITIS IN CHILDREN | 2000 |
|
RU2187992C2 |
| METHOD OF PREDICTING GASTRODUODENAL PATHOLOGY COURSE IN CHILDREN | 2011 |
|
RU2475754C2 |
| METHOD OF EVALUATING EFFECTIVENESS BASIC ANTI-INFLAMMATORY THERAPY OF BRONCHIAL ASTHMA IN CHILDREN | 2008 |
|
RU2354970C1 |
